Related Experiment Videos
Intravesical therapy for bladder cancer.
1Department of Urology, University of Tennessee, Memphis.
The Urologic Clinics of North America
|November 1, 1988
Summary
Treatment for non-muscle invasive bladder cancer varies by grade. Low-grade tumors require less aggressive approaches, while high-grade tumors necessitate careful monitoring and intravesical therapy. Ongoing trials will clarify optimal treatments.
Area of Science:
- Urology
- Oncology
Background:
- Bladder tumors confined to the mucosa and lamina propria exhibit heterogeneity.
- Noninvasive papillary, low-grade tumors (Ta) frequently recur but rarely progress.
- High-grade tumors (carcinoma in situ, Ta, or T1) demand thorough resection and vigilant monitoring.
Purpose of the Study:
- To review current understanding of intravesical therapies for non-muscle invasive bladder cancer.
- To discuss the efficacy and side effects of various intravesical agents.
- To highlight the need for further research and randomized trials.
Main Methods:
- Review of existing literature on intravesical therapies for bladder cancer.
- Discussion of specific agents including Thiotepa, Mitomycin C, Adriamycin, and BCG.
- Analysis of treatment approaches based on tumor grade and stage.
Main Results:
- Thiotepa can delay low-grade tumor development with low toxicity and cost.
- Mitomycin C is effective for residual tumor treatment and prophylaxis, with infrequent, mild side effects but is expensive.
- BCG may be most effective for carcinoma in situ, but carries risks of local and systemic side effects.
Conclusions:
- Intravesical therapy is crucial for high-grade non-muscle invasive bladder cancer to prevent muscle invasion.
- The optimal intravesical agent for specific circumstances is not yet definitively established.
- Randomized trials are ongoing to determine the most appropriate intravesical agents and treatment protocols.